Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Oncolytics Biotech Inc
(TSX:
ONC
)
1.470
-0.020 (-1.34%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
14,646
Open
1.480
Bid (Size)
1.470 (5)
Ask (Size)
1.490 (2)
Prev. Close
1.490
Today's Range
1.450 - 1.490
52wk Range
1.200 - 4.490
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Biotech Innovations Paving the Way in Breast Cancer Fight
April 11, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Product Safety
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
April 11, 2024
Requested for Q2 2024, the Type C meeting is to focus on planned registration-enabling trial in HR+/HER2- metastatic breast cancer Overall survival results from the randomized HR+/HER2- metastatic...
Via
FinancialNewsMedia
Exposures
Product Safety
Performance
YTD
-16.48%
-16.48%
1 Month
+1.38%
+1.38%
3 Month
-10.91%
-10.91%
6 Month
-32.26%
-32.26%
1 Year
-23.83%
-23.83%
More News
Read More
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
March 14, 2024
Via
FinancialNewsMedia
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth
March 06, 2024
Via
FinancialNewsMedia
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning
March 06, 2024
Via
Newsfile
Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
March 05, 2024
Via
FinancialNewsMedia
Cancer Immunotherapy Stocks – Tapping into Immune Systems for Next Generation Treatments
February 15, 2024
Via
FinancialNewsMedia
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
March 05, 2024
Via
FinancialNewsMedia
Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments
February 15, 2024
Via
Newsfile
Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
February 14, 2024
Via
FinancialNewsMedia
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
March 05, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Pancreatic Cancer Treatments Poised for Major Advances in 2024
February 07, 2024
Via
FinancialNewsMedia
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
February 14, 2024
Via
FinancialNewsMedia
Stocks Recoup Post-Fed Losses As Traders Challenge Powell, Regional Banks Crack, Gold Rises: What's Driving Markets Thursday?
February 01, 2024
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
February 14, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
January 09, 2024
Via
FinancialNewsMedia
Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors
January 09, 2024
Via
FinancialNewsMedia
Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024
January 04, 2024
Via
FinancialNewsMedia
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
January 09, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
November 29, 2023
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance
November 09, 2023
Via
FinancialNewsMedia
Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy
November 09, 2023
Via
FinancialNewsMedia
Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise
October 23, 2023
Via
FinancialNewsMedia
Exposures
Product Safety
Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing
October 23, 2023
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study
October 23, 2023
Via
FinancialNewsMedia
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.